Group 1 - Heng Rui Medicine signed an agreement with GSK for the global exclusive rights of the HRS-9821 project and up to 11 additional projects, potentially worth around $12 billion [1] - GSK will pay Heng Rui a $500 million upfront payment, with additional milestone payments based on successful development, registration, and sales [1] - Heng Rui's stock surged, closing at 62.04 CNY per share, with a market capitalization exceeding 400 billion CNY, indicating strong market sentiment towards the innovative drug sector [1] Group 2 - Eli Lilly's drug, Tirzepatide injection, received approval from China's NMPA for a new indication to improve blood sugar control in adult patients with type 2 diabetes [2] - The new indication allows for the combination of Tirzepatide with insulin, providing a better treatment option for patients who do not respond well to insulin alone [2] - This approval helps Eli Lilly strengthen its market share in the diabetes treatment sector in China [2] Group 3 - Hotgen Biotech developed an antibody test kit for Chikungunya virus, enabling rapid qualitative detection within 15 minutes [3] - The test kit is designed for use in suspected case screening and large-scale monitoring, although it has not yet received regulatory approval for medical use [3] - The stock price of Hotgen Biotech increased by 6.88%, reflecting market response to the potential impact of the test kit amid a Chikungunya outbreak [4] Group 4 - WuXi AppTec reported a net profit of 8.561 billion CNY for the first half of 2025, a year-on-year increase of 101.92% [5] - The company achieved a revenue of 20.799 billion CNY, up 20.64% year-on-year, and plans to distribute a cash dividend of 3.5 CNY per 10 shares [5] - WuXi AppTec raised its revenue guidance for 2025, expecting a growth rate of 13% to 17% [5][6]